VITAMIN D LEVELS IN PATIENTS WITH INSULIN RESISTANCE

Authors

DOI:

https://doi.org/10.5281/zenodo.8266768

Keywords:

Insulin resistance, vitamin D, HbA1c

Abstract

*The abstract of this article was presented as an oral presentation at the 3rd INTERNATIONAL ZEUGMA CONFERENCE ON SCIENTIFIC RESEARCHES (November 22-24, 2019 GAZIANTEP, TURKEY).

ABSTRACT

Introduction-Aim: Insulin resistance is the decrease in the response of target tissues (muscle, liver and adipose tissue) to insulin. Insulin resistance is thought to be one of the primary defects underlying the development of Type 2 diabetes mellitus (T2DM). Vitamin D is a steroid prohormone that is produced mainly from 7-dehydrocholesterol in the skin under the influence of ultraviolet light, and is responsible for regulating blood levels of calcium and phosphorus and maintaining the proper continuation of bone turnover. The results of recent studies show that vitamin D deficiency is associated with insulin resistance, T2DM and metabolic syndrome. The positive effects of vitamin D replacement on the treatment of patients with insulin resistance and diabetes mellitus were determined. It has been shown that low vitamin D levels are associated with insulin resistance in non-diabetic obese individuals. It has been observed that vitamin D insufficiency is an increasing public health problem in developed and developing countries. It has been understood that vitamin D has many important functions apart from its classical effects on the bone-muscle system. Vitamin D has been found to be associated with chronic diseases such as cardiovascular diseases, metabolic syndrome and T2DM. It has been determined that 25-hydroxyvitamin D [25(OH)D] levels in the blood are associated with obesity, metabolic syndrome and diabetes.

The aim of this study is to examine vitamin D levels in individuals with high insulin resistance (HOMA-IR values), which is an indicator of insulin sensitivity in the whole body. In this study, it was aimed to compare 25-hydroxyvitamin D concentrations between individuals without a history of insulin resistance, diabetes mellitus and any disease and those with insulin resistance, and to investigate the possible effects of vitamin D on glucose homeostasis.

Method: The cases were divided into 2 groups as those with and without insulin resistance. Vitamin D levels of both groups were compared. The Homeostasis Model Evaluation score of Insulin Resistance (HOMA-IR) was calculated with the formula: HOMA-IR=[fasting glucose (mg/dl) X fasting insulin (µU/ml)]/405. Those with a HOMA-IR score of ≥ 2.5 were considered to have insulin resistance. A total of 58 patients with insulin resistance (43 females, 15 males, mean age; 36.20±13.25 years) and a control group of 56 individuals (48 females, 8 males, mean age; 35.14±10.96 years) without insulin resistance were included in the study.

Results: When the vitamin D levels of the control group and the patients with insulin resistance were compared, the vitamin D levels were found to be low in the insulin resistance group, but it was not statistically significant (27.67±9.71 ng/ml and 24.27±10.09 ng/ml, respectively; p = 0.07).

Conclusion: The results of recent studies show that vitamin D deficiency is associated with insulin resistance, type 2 diabetes mellitus and metabolic syndrome. In this study, we did not find a significant difference in 25-hydroxyvitamin D levels between the groups. Further studies are needed to determine the interaction between insulin resistance, diabetes mellitus and vitamin D.

Keywords: Insulin resistance, vitamin D, HbA1c

References

-Andersen JL, Schjerling P, Andersen LL, Dela F. Resistance training and insulin action in humans: Effects of detraining. J Physiol (Lond) 2003;551:1049–1058.

-Befroy DE, Petersen KF, Dufour S, Mason GF, de Graaf RA, Rothman DL, Shulman GI. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes. 2007;56:1376–1381.

-Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci. 2002;967:146–157.

-Turban S, Hajduch E. Protein kinase C isoforms: Mediators of reactive lipid metabolites in the development of insulin resistance. FEBS letters. 2011;585:269–274.

-Institute of Medicine (IoM) In: Dietary Reference Intakes for Calcium and Vitamin D. Ross A.C., Taylor C.L., Yaktine A.L., Del Valle H.B., editors. The National Academies Press; Washington, DC, USA: 2011.

-Bikle D.D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 2014;21:319–329.

-Gil A., Plaza-Diaz J., Mesa M.D. Vitamin D: Classic and Novel Actions. Ann. Nutr. Metab. 2018;72:87–95.

-Wang H., Chen W., Li D., Yin X., Zhang X., Olsen N., Zheng S.G. Vitamin D and Chronic Diseases. Aging Dis. 2017;8:346–353.

-Tao S., Yuan Q., Mao L., Chen F.-L., Ji F., Cui Z.-H. Vitamin D deficiency causes insulin resistance by provoking oxidative stress in hepatocytes. Oncotarget. 2017;8:67605–67613.

-Tabesh M., Azadbakht L., Faghihimani E., Tabesh M., Esmaillzadeh A. Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: A randomised controlled clinical trial. Diabetologia. 2014;57:2038–2047.

-Upreti V., Maitri V., Dhull P., Handa A., Prakash M.S., Behl A. Effect of oral vitamin D supplementation on glycemic control in patients with type 2 diabetes mellitus with coexisting hypovitaminosis D: A parellel group placebo controlled randomized controlled pilot study. Diabetes Metab. Syndr. 2018;12:509–512.

-Ana Lúcia Farias de Azevedo Salgado, Luciana de Carvalho, Ana Claudia Oliveira, Virgínia Nascimento dos Santos, Jose Gilberto Vieira, Edison Roberto Parise. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010 Apr-Jun;47(2):165-9.

-Artunc F et al. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016 Dec;12(12):721-737.

-Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin d status of the us population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008;88:1519–1527.

-Kasuga M. Insulin Resistance and Pancreatic Beta Cell Failure. J. Clin. Investig. 2006;116:1756–1760. doi: 10.1172/JCI29189.

-Schwartz S.S., Epstein S., Corkey B.E., Grant S.F.A., Gavin I.J.R., Aguilar R.B., Herman M.E. A Unified Pathophysiological Construct of Diabetes and its Complications. Trends Endocrinol. Metab. 2017;28:645–655.

-Al Mheid I., Patel R.S., Tangpricha V., Quyyumi A.A. Vitamin D and Cardiovascular Disease: Is the Evidence Solid? Eur. Heart J. 2013;34:3691–3698.

-Seo J.A., Eun C.R., Cho H., Lee S.K., Yoo H.J., Kim S.G. Low Vitamin D Status is Associated with Non-alcoholic Fatty Liver Disease Independent of Visceral Obesity in Korean Adults. PLoS ONE. 2013;8:e751.

-Dattola A., Silvestri M., Bennardo L., Passante M., Scali E., Patruno C., Nistico S.P. Role of Vitamins in Skin Health: A Systematic Review. Curr. Nutr. Rep. 2020;9:226–235.

-Chiu K.C., Chu A., Go V.L.W., Saad M.F. Hypovitaminosis D is Associated with Insulin Resistance and Cell Dysfunction. Am. J. Clin. Nutr. 2004;79:820–825.

-Pittas A.G., Lau J., Hu F.B. Dawson-Hughes, B. The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 2007;92:2017–2029.

-Kositsawat J., Freeman V., Gebber B., Geraci S. Association of A1c Levels with Vitamin D Status in U.S. Adults. Diabetes Care. 2010;33:1236–1238.

-Hypponen E., Power C. Vitamin D Status and Glucose Homeostasis in the 1958 British Bird Cohort: The role of obesity. Diabetes Care. 2006;29:2244–2246.

-Gulseth H.L., Gjelstad I.M.F., Tierney A.C., Lovengrove J.A., Defoort C., Blaak E.E., Lopez-Miranda J., Kiec-Wilk B., Ris U., Roshe H., et al. Serum Vitamin D Concentration Does Not Predict Insulin Action or Secretion in European Subjects with the Metabolic Syndrome. Diabetes Care. 2010;33:923–925.

-Bril F., Maximos M., Portillo-Sanchez P., Biernacki D., Lomonaco R., Subbarayan S., Correa M., Lo M., Suman A., Cusi K. Relationship of Vitamin D with Insulin Resistance and Disease Severity in Non-alcoholic Steatohepatitis. J. Hepatol. 2015;62:405–411.

-Chung S.J., Lee Y.A., Hong H., Kang M.J., Kwon H.J., Shin C.H., Yang S.W. Inverse Relationship between Vitamin D Status and Insulin Resistance and the Risk of Impaired Fasting Glucose in Korean Children and Adolescents: The Korean National Health and Nutrition Examination Survey (KNHANES) 2009–2010. Public Health Nutr. 2014;17:795–802.

-Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25‐hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990‐2000. Diabetes 2008;57:2619‐2625.

-Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta‐cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33:1379‐1381.

-Pereira‐Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D deficiency: a systematic review and meta‐analysis. Obes Rev 2015;16:341‐349.

-Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690‐693.

-Wamberg L, Christiansen T, Paulsen SK, et al. Expression of vitamin D‐metabolizing enzymes in human adipose tissue‐the effect of obesity and diet‐induced weight loss. Int J Obes (Lond) 2012;37:651‐657.

-Hyppönen E., Boucher B.J. Adiposity, vitamin D requirements, and clinical implications for obesity-related metabolic abnormalities. Nutr. Rev. 2018;76:678–692.

-Marquina C., Mousa A., Scragg R., De Courten B. Vitamin D and cardiometabolic disorders: A review of current evidence, genetic determinants and pathomechanisms. Obes. Rev. 2018;20:262–277.

-McGill A.-T., Stewart J.M., Lithander F.E., Strik C.M., Poppitt S.D. Relationships of low serum vitamin D3with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr. J. 2008;7:4.

-Fu Z., Xu C., Shu Y., Xie Z., Lu C., Mo X. Serum 25-hydroxyvitamin D is associated with obesity and metabolic parameters in US children. Public Health Nutr. 2019;23:1214–1222.

-Perna S. The enigma of vitamin D supplementation in aging with obesity. Minerva Gastroenterol. 2021 doi: 10.23736/S2724-5985.21.02955-7.

-Walsh J.S., Evans A.L., Bowles S., Naylor K.E., Jones K.S., Schoenmakers I., Jacques R.M., Eastell R. Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health. Am. J. Clin. Nutr. 2016;103:1465–1471.

-Konradsen S., Ag H., Lindberg F., Hexeberg S., Jorde R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur. J. Nutr. 2008;47:87–91.

-Pramono A., Jocken J.W.E., Goossens G.H., Blaak E.E. Vitamin D release across abdominal adipose tissue in lean and obese men: The effect of ß-adrenergic stimulation. Physiol. Rep. 2019;7:e14308.

Published

2023-06-20

How to Cite

Doğantekin, A. (2023). VITAMIN D LEVELS IN PATIENTS WITH INSULIN RESISTANCE. EJONS INTERNATIONAL JOURNAL, 7(2), 319–328. https://doi.org/10.5281/zenodo.8266768